Zelapar
Zelapar is a drug that is useful in treating patients with Parkinson’s disease. Tablets of Zelapar are composed of an active ingredient known as selegiline hydrochloride. This ingredient belongs to a category of medicine that is known as a selective monoamine-oxidase-B inhibitor (MAOI-B). The ingredient seligiline increases the production of a substance to be found in the brain known as dopamine. Dopamine is a neurotransmitter that is present in the brain. These neurotransmitters send signals back and forth between the brain and the nervous system. The functioning of a normal, healthy human being requires that the neurotransmitters do their job properly.
Those who suffer from Parkinson’s disease either have less dopamine in their brains than those who don’t suffer from it, or else they have none at all. It is the decrease or absence of dopamine that is believed to be responsible for the symptoms of this debilitating disease. In this way, Zelapar works to replace the level of dopamine in the brains of Parkinson’s sufferers thereby improving their quality of life.
Zelapar are available as tablets and they are placed on the tongue and from there they dissolve. Water is not required for them to work properly. To take one, be careful to peel the foil off of the tablet and then remove it from the package gingerly. The tablet must be taken in the morning, approximately five minutes before you sit down to eat breakfast. It must be dissolved completely before any food is consumed. Also do not drink anything or rinse your mouth out until you are guaranteed that the pill has been absorbed by your system. This can take anywhere from three to six or seven minutes from start to finish.
Those who have experienced problems with their liver, who have a family history of peptic ulcers, should take this drug with caution. Advise your doctor of any and all health conditions before you begin taking Zelapar.
Disclaimer: Cliff Schaffer does not personally endorse or support any of the comments made within the writings of this article. |
